A carregar...
PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA
The U.S. Food and Drug Administration recently approved two poly‐adenosine diphosphate‐ribose polymerase (PARP) inhibitors, olaparib and rucaparib, for treatment of biomarker‐positive metastatic castrate resistant prostate cancer. The benefits of PARP inhibition have been well characterized in patie...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7794174/ https://ncbi.nlm.nih.gov/pubmed/32790034 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0697 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|